Clinical Scorecard: Roswell Park Quick Talks: Breast Cancer and ADCs, Risk of Second HPV-Related Cancer, Cognitive Function and ICIs

At a Glance

Key Highlights

• 83.7% survival beyond 5 years with ADCs in HER2-positive metastatic breast cancer.
• Racial disparities observed in breast cancer outcomes, with Asian patients having the highest survival rates.
• Increased risk of second HPV-related cancers in survivors of HPV-associated first primary cancers.
• Cognitive function declines in patients treated with ICIs, particularly in women and Black patients under 65.

Guideline-Based Recommendations

Diagnosis

• Monitor for racial and ethnic disparities in breast cancer outcomes.
• Assess HPV status in cancer survivors for risk of second malignancies.

Management

• Utilize ADCs for HER2-positive metastatic breast cancer.
• Implement strategies to address disparities in treatment outcomes.

Monitoring & Follow-up

• Regular cognitive assessments for patients undergoing ICI treatment.
• Surveillance for second cancers in HPV-associated cancer survivors.

Risks

• Higher risk of second cancers in female HPV cancer survivors.
• Cognitive decline in patients receiving ICIs.

Patient & Prescribing Data

Patients with metastatic HER2-positive breast cancer and HPV-associated cancers.

ADCs show significant survival benefits; increased vigilance required for second cancer risks.

Clinical Best Practices

• Incorporate ADCs in treatment plans for eligible breast cancer patients.
• Educate patients on the risks of second cancers related to HPV.
• Monitor cognitive function in patients receiving ICIs.

References

• Roswell Park Comprehensive Cancer Center